基本情報

写真a

下川　晃彦(シモカワ　テルヒコ)

SHIMOKAWA Teruhiko


ホームページ

https://tmdu-oi.jp

研究分野・キーワード

創薬, 医薬品研究開発
このページの先頭へ▲

出身大学院 【 表示 ／ 非表示 】

  • 名古屋市立大学大学院  薬学研究科  博士課程  1989年03月  修了

このページの先頭へ▲

取得学位 【 表示 ／ 非表示 】

  • 博士（薬学）  名古屋市立大学

このページの先頭へ▲

経歴(学内) 【 表示 ／ 非表示 】

  • 2023年04月
    -
    現在
    東京医科歯科大学 統合イノベーション機構 オープンイノベーションセンター 特任教授
  • 2023年03月
    　
    　
    東京医科歯科大学 統合イノベーション機構 オープンイノベーションセンター クリエイティブ・マネージャー（教員）
  • 2021年12月
    -
    2023年02月
    東京医科歯科大学 オープンイノベーション機構 クリエイティブ・マネージャー（教員）
このページの先頭へ▲

経歴(学外) 【 表示 ／ 非表示 】

  • 1999年12月
    　
    　
    The Johns Hopkins University School of Medicine, Department of Biological Chemistry Research Fellow
  • 1989年08月
    　
    　
    Michigan State University Department of Biochemistry Post-doctoral Research Fellow
  • 2020年03月
    　
    　
    Japan Agency for Medical Research and Development Department of Intellectual Property IP Consultant
  • 2012年04月
    　
    　
    Astellas Pharma Inc. Department of Clinical Development Global Project Management Lead, GPML
  • 2005年04月
    　
    　
    Astellas Pharma Inc. Department of Drug Discovery Research Principal Investigator, 主席研究員, 次長
  • 1991年11月
    　
    　
    Yamanouchi Pharmaceutical Co., Ltd. Department of Drug Discovery Research Principal Investigator, 主席研究員, 次長
  • 1989年04月
    　
    　
    Japan Society for the Promotion of Science Research Fellowship for Young Scientists, 日本学術振興会特別研究員

▼全件表示

このページの先頭へ▲

所属学協会 【 表示 ／ 非表示 】

  • 米国内分泌学会 (ENDO)

  • 米国心臓学会 (AHA)

  • 一般社団法人 日本知財学会

  • 日本薬学会

  • 日本動脈硬化学会

  • 日本脂質生化学会

  • 日本ファージセラピー研究会

▼全件表示

このページの先頭へ▲

委員歴 【 表示 ／ 非表示 】

  • 2024年03月
    　
    　
    厚生労働省 「国内外の感染症治療薬開発動向等調査事業」政策・支援対象検討会 検討委員（委員長）
  • 2024年04月
    -
    現在
    最高裁判所 知的財産高等裁判所 専門委員
  • 2024年04月
    -
    現在
    国立研究開発法人日本医療研究開発機構（AMED) AMED課題評価委員　創薬ベンチャーエコシステム強化事業 創薬ベンチャー専門委員
  • 2023年04月
    -
    現在
    国立研究開発法人日本医療研究開発機構（AMED) B型肝炎創薬実用化等研究事業 プログラムオフィサー（PO）
  • 2023年04月
    -
    現在
    国立研究開発法人日本医療研究開発機構（AMED) 肝炎等克服緊急対策研究事業 プログラムオフィサー（PO）
  • 2022年01月
    -
    2023年03月
    国立研究開発法人日本医療研究開発機構 AMED プログラムオフィサー PO（肝炎等克服実用化研究事業）
  • 2022年04月
    -
    2024年03月
    国立研究開発法人日本医療研究開発機構 AMED 課題評価委員（創薬ベンチャーエコシステム強化事業）
  • 2022年03月
    　
    　
    国立研究開発法人日本医療研究開発機構 AMED 科学技術調査員

▼全件表示

このページの先頭へ▲

研究分野 【 表示 ／ 非表示 】

  • 分子生物学

  • 代謝、内分泌学

  • 病態医化学

  • 薬理学

  • 細胞生物学

  • 薬系化学、創薬科学

  • 腎臓内科学

▼全件表示

このページの先頭へ▲

資格、免許 【 表示 ／ 非表示 】

  • 第一種放射線取扱主任者

  • 薬剤師

このページの先頭へ▲
 

論文・総説 【 表示 ／ 非表示 】

  1. Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T, Shibasaki M. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sciences. 2014.01; 94 (2): 115-21. ( PubMed, DOI )

  2. Suwa A, Yoshino M, Kurama T, Shimokawa T, Aramori I. Glucose regulates RMI1 expression through the E2F pathways in adipose cells. Endocrine. 2011.08; 40 (1): 56-61. ( PubMed, DOI )

  3. Tanaka H, Shimaya A, Kiso T, Kuramochi T, Shimokawa T, Shibasaki M. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sciences. 2011.03; 88 (11-12): 559-63. ( PubMed, DOI )

  4. Suwa A, Shimokawa T. Emerging targets for the treatment of obesity. The FEBS Journal. 2011.02; 278 (4): 551. ( PubMed, DOI )

  5. Suwa A, Kurama T, Shimokawa T. Adipocyte hyperplasia and RMI1 in the treatment of obesity. The FEBS Journal. 2011.02; 278 (4): 565-9. ( PubMed, DOI )

  6. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T, Shibasaki M. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Molecular Pharmacology. 2010.11; 78 (5): 961-70. ( PubMed, DOI )

  7. Tanaka H, Nagashima T, Shimaya A, Urano Y, Shimokawa T, Shibasaki M. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. European Journal of Pharmacology. 2010.10; 645 (1-3): 185-91. ( PubMed, DOI )

  8. Suwa A, Kurama T, Yamamoto T, Sawada A, Shimokawa T, Aramori I. Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. European Journal of Pharmacology. 2010.09; 642 (1-3): 177-82. ( PubMed, DOI )

  9. Suwa A, Kurama T, Shimokawa T. SHIP2 and its involvement in various diseases. Expert Opinion on Therapeutic Targets. 2010.07; 14 (7): 727-37. ( PubMed, DOI )

  10. Suwa A, Yoshino M, Yamazaki C, Naitou M, Fujikawa R, Matsumoto S, Kurama T, Shimokawa T, Aramori I. RMI1 deficiency in mice protects from diet and genetic-induced obesity. The FEBS Journal. 2010.02; 277 (3): 677-86. ( PubMed, DOI )

  11. A. Suwa, T. Yamamoto, A. Sawada, K. Minoura, N. Hosogai, A. Tahara, T. Kurama, T. Shimokawa, I. Aramori. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2: RESEARCH PAPER British Journal of Pharmacology. 2009.10; 158 (3): 879-887. ( PubMed, DOI )

  12. Wolfgang MJ, Cha SH, Millington DS, Cline G, Shulman GI, Suwa A, Asaumi M, Kurama T, Shimokawa T, Lane MD. Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. Journal of Neurochemistry. 2008.05; 105 (4): 1550-9. ( PubMed, DOI )

  13. Wolfgang MJ, Kurama T, Dai Y, Suwa A, Asaumi M, Matsumoto S, Cha SH, Shimokawa T, Lane MD. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 2006.05; 103 (19): 7282-7. ( PubMed, DOI )

  14. S. Terada, K. Kawanaka, M. Goto, T. Shimokawa, I. Tabata. Effects of high-intensity intermittent swimming on PGC-1α protein expression in rat skeletal muscle Acta Physiologica Scandinavica. 2005.05; 184 (1): 59-65. ( PubMed, DOI )

  15. M. Kato, A. Suwa, T. Shimokawa. Glucose catabolic gene mRNA levels in skeletal muscle exhibit non-coordinate expression in hyperglycemic mice Hormone and Metabolic Research. 2004.08; 36 (8): 513-518. ( PubMed, DOI )

  16. Hori Shinichiro, Yamada Makoto, Ohtani Sachiko, Hori Chiyo, Yokomizo Tadahiro, Webb Timothy, Shimokawa Teruhiko. Myonase is Localized in Skeletal Muscle Myofibrils. The Journal of Biochemistry. 2002.09; 132 (3): 417-425. ( 医中誌 )

  17. Terada S, Goto M, Kato M, Kawanaka K, Shimokawa T, Tabata I. Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. Biochemical and Biophysical Research Communications. 2002.08; 296 (2): 350-4. ( PubMed, DOI )

  18. Kumar MV, Shimokawa T, Nagy TR, Lane MD. Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice. Proceedings of the National Academy of Sciences of the United States of America. 2002.02; 99 (4): 1921-5. ( PubMed, DOI )

  19. Shimokawa T, Kumar MV, Lane MD. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proceedings of the National Academy of Sciences of the United States of America. 2002.01; 99 (1): 66-71. ( PubMed, DOI )

  20. Teruhiko Shimokawa, Mitsuhiro Kagami, Miyuki Kato, Eiji Kurosaki, Masayuki Shibasaki, Masao Katoh. Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells European Journal of Pharmacology. 2000.12; 410 (1): 1-5. ( PubMed, DOI )

  21. Masahide Goto, Shin Terada, Miyuki Kato, Masao Katoh, Toshiko Yokozeki, Izumi Tabata, Teruhiko Shimokawa. cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats Biochemical and Biophysical Research Communications. 2000.08; 274 (2): 350-354. ( PubMed, DOI )

  22. Teruhiko Shimokawa, Miyuki Kato, Mitsuhiro Kagami, Yoshitaka Ueda, Eiji Kurosaki, Tatsuya Maruyama, Masayuki Shibasaki, Masao Katoh. Glucose uptake stimulator YM-138552 activates gene expression and translocation of glucose transporter isotype 4 Drug Development Research. 2000; 51 (1): 43-48. ( DOI )

  23. Cha Seung Hun, Kyoko Hasegawa, Terue Kawabata, Miyuki Kato, Teruhiko Shimokawa, Yasuo Kagawa. Increased uncoupling protein2 mRNA in white adipose tissue, and decrease in leptin, visceral fat, blood glucose, and cholesterol in KK-A(y) mice fed with eicosapentaenoic and docosahexaenoic acids in addition to linolenic acid Biochemical and Biophysical Research Communications. 1999.05; 259 (1): 85-90. ( PubMed, DOI )

  24. Shoichiro Goto, Teruhiko Shimokawa. Effect of the hypocholesterolemic agent YM-16638 on cholesterol biosynthesis activity and apolipoprotein B secretion in HepG2 and monkey liver Japanese Journal of Pharmacology. 1999; 79 (1): 75-82. ( PubMed, DOI )

  25. Teruhiko Shimokawa, Miyuki Kato, Yuka Watanabe, Reiko Hirayama, Eiji Kurosaki, Hisataka Shikama, Seiichi Hashimoto. In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice Biochemical and Biophysical Research Communications. 1998.10; 251 (1): 374-378. ( PubMed, DOI )

  26. Teruhiko Shimokawa, Miyuki Kato, Osamu Ezaki, Seiichi Hashimoto. Transcriptional regulation of muscle-specific genes during myoblast differentiation Biochemical and Biophysical Research Communications. 1998.05; 246 (1): 287-292. ( PubMed, DOI )

  27. Teruhiko Shimokawa, Shoichiro Goto, Motoko Ida, Masahide Goto, Satomi Nishijima, Tatsuhiko Kodama. Hypocholesterolemic effects of the LDL receptor gene transcriptional upregulator CP-230821 Journal of Biochemistry. 1998.04; 123 (4): 596-601. ( PubMed, DOI )

  28. Teruhiko Shimokawa, Miyuki Kato, Koichi Shioduka, Jun Irie, Osamu Ezaki. Effect of triiodothyronine on muscle cell differentiation and blood glucose level in hyperglycemic KK mice Biochemical and Biophysical Research Communications. 1997.06; 235 (3): 790-793. ( PubMed, DOI )

  29. Teruhiko Shimokawa, Shoichiro Goto, Tohru Ugawa, Nami Hisamichi, Shin Naganuma, Yuichi Iizumi, Noboru Sato, Toichi Takenaka, Tatsuhiko Kodama. Cholesterol-lowering effect of YM-16638 in cynomolgus monkeys Drug Development Research. 1996.06; 38 (2): 86-92. ( DOI )

  30. Shoichiro Goto, Teruhiko Shimokawa, Toru Ugawa, Nami Hisamichi, Youichi Masuyama, Yuichi Iizumi, Noboru Sato, Toichi Takenaka, Tatsuhiki Kodama. Species specificity in the blood cholesterol-lowering effect of YM-16638 British Journal of Pharmacology. 1996; 118 (1): 174-178. ( PubMed, DOI )

  31. T. Shimokawa, T. Ugawa, S. Goto, N. Sato, T. Takenaka, T. Kodama. Effect of YM-16638, an orally active leukotriene antagonist, on alanine aminotransferase activity in-vitro and in-vivo Pharmaceutical Sciences. 1996; 2 (10): 483-486.

  32. Yoshiki Kawabe, Teruhiko Shimokawa, Akiyo Matsumoto, Makoto Honda, Yoichiro Wada, Yoshio Yazaki, Akira Endo, Hiroshige Itakura, Tatsuhiko Kodama. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells Biochemical and Biophysical Research Communications. 1995.03; 208 (1): 405-411. ( PubMed, DOI )

  33. T. Shimokawa, Y. Kawabe, M. Honda, Y. Yazaki, A. Matsumoto, H. Itakura, T. Kodama. Determination of mRNA levels of cholesterol biosynthesis enzymes and LDL receptor using ribonuclease protection assay Journal of Lipid Research. 1995; 36 (9): 1919-1924. ( PubMed )

  34. Teruhiko Shimokawa, William L. Smith. Expression of prostaglandin endoperoxide synthase-1 in a baculovirus system Biochemical and Biophysical Research Communications. 1992.03; 183 (3): 975-982. ( PubMed, DOI )

  35. T. Shimokawa, W. L. Smith. Prostaglandin endoperoxide synthase. The aspirin acetylation region Journal of Biological Chemistry. 1992; 267 (17): 12387-12392. ( PubMed )

  36. Keiko Sakai, Teruhiko Shimokawa, Tetsuyuki Kobayashi, Harumi Okuyama. Lipid Lowering Effects of High Linoleate and High a-Linolenate Diets in Rats and Mice: Consequence of Long-Term Feedings Chemical and Pharmaceutical Bulletin. 1992; 40 (8): 2129-2132. ( PubMed, DOI )

  37. TAKAUE, Y; WATANABE, T; HOSHI, Y; ABE, T; MATSUNAGA, K; SAITO, S; HIRAO, A; KAWANO, Y; NINOMIYA, T; KURODA, Y; KOYAMA, T; SUZUE, T; SHIMOKAWA, T; UCHIYAMA, H; WATANABE, A; MATSUSHITA, T; KIKUTA, A; YOKOBAYASHI, A; MURAKAMI, R; MANABE, A; HOSOYA, R; OHIRA, M; FUJIMOTO, T. EFFECTIVENESS OF HIGH-DOSE MCNU THERAPY AND HEMATOPOIETIC STEM-CELL AUTOGRAFTS TREATMENT OF CHILDHOOD ACUTE-LEUKEMIA LYMPHOMA WITH HIGH-RISK FEATURES CANCER. 1991.04; 67 (7): 1830-1837. ( PubMed, DOI )

  38. T. Shimokawa, W. L. Smith. Essential histidines of prostaglandin endoperoxide synthase: His-309 is involved in heme binding Journal of Biological Chemistry. 1991; 266 (10): 6168-6173. ( PubMed )

  39. W. L. Smith, D. L. DeWitt, T. Shimokawa. The aspirin and heme binding sites of PGG/H synthase. Advances in prostaglandin, thromboxane, and leukotriene research. 1991; 21 A 77-80. ( PubMed )

  40. William L. Smith, David L. DeWitt, Teruhiko Shimokawa, Stacey A. Kraemer, Elizabeth A. Meade. Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents Stroke. 1990.12; 21 (12): IV-24. ( PubMed )

  41. T. Shimokawa, R. J. Kulmacz, D. L. DeWitt, W. L. Smith. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis Journal of Biological Chemistry. 1990; 265 (33): 20073-20076. ( PubMed )

  42. W. L. Smith, D. L. DeWitt, S. A. Kraemer, M. J. Andrews, T. Hla, T. Maciag, T. Shimokawa. Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases. Advances in prostaglandin, thromboxane, and leukotriene research. 1990; 20 14-21. ( PubMed )

  43. Hiromi Hayashi, Koji Ueno, Takamitsu Hori, Yukio Naito, Teruhiko Shimokawa, Harumi Okuyama. Hypertension does not stimulate the development of hypercholesterolemia or fatty liver induced by a high cholesterol/cholate diet in rats Chemical and Pharmaceutical Bulletin. 1989; 37 (7): 1844-1848. ( PubMed, DOI )

  44. Teruhiko Shimokawa, Atsuko Moriuchi, Takamitsu Hori, Masaki Saito, Yukio Naito, Hidehiro Kabasawa, Yuji Nagae, Michitaka Matsubara, Harumi Okuyama. Effect of dietary alpha-linolenate/linoleate balance on mean survival time, incidence of stroke and blood pressure of spontaneously hypertensive rats Life Sciences. 1988; 43 (25): 2067-2075. ( PubMed, DOI )

  45. Mitsuo Nakagawa, Noriyuki Ishihara, Teruhiko Shimokawa, Shoji Kojima. Effect of clofibrate on lipid peroxidation in rats treated with aspirin and 4-pentenoic acid Journal of Biochemistry. 1987.01; 101 (1): 81-88. ( PubMed, DOI )

  46. Ruth Juliet A. Villegas, Teruhiko Shimokawa, Harumi Okuyama, Mineo Kojima. Purification and characterization of chlorogenic acid: chlorogenate caffeoyl transferase in sweet potato roots Phytochemistry. 1987; 26 (6): 1577-1581. ( DOI )

  47. M. Nakagawa, T. Shimokawa, A. Noguchi, N. Ishihara, S. Kojima. Effect of clofibrate on cholesterol metabolism in rats treated with polychlorinated biphenyls Lipids. 1986.02; 21 (2): 159-163. ( PubMed, DOI )

  48. Mitsuo Nakagawa, Teruhiko Shimokawa, Shoji Kojima. Effects of Clofibrate on Hyperlipidemia Induced by Polychlorinated Biphenyls and Elimination of Polychlorinated Biphenyls Accumulated in Rat Tissues Chemical and Pharmaceutical Bulletin. 1986; 34 (9): 3940-3944. ( PubMed, DOI )

  49. Shimokawa T, Kumar MV, Lane MD. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002.01; 99 (1): 66-71.

  50. SHIMOKAWA T, SMITH WL. PROSTAGLANDIN ENDOPEROXIDE SYNTHASE - THE ASPIRIN ACETYLATION REGION JOURNAL OF BIOLOGICAL CHEMISTRY. 1992.06; 267 (17): 12387-12392.

  51. SHIMOKAWA T, SMITH WL. EXPRESSION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1 IN A BACULOVIRUS SYSTEM BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1992.03; 183 (3): 975-982.

  52. SHIMOKAWA T, SMITH WL. ESSENTIAL HISTIDINES OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE - HIS-309 IS INVOLVED IN HEME BINDING JOURNAL OF BIOLOGICAL CHEMISTRY. 1991.04; 266 (10): 6168-6173.

  53. SMITH WL, DEWITT DL, SHIMOKAWA T. THE ASPIRIN AND HEME BINDING-SITES OF PGG/H SYNTHASE ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH. 1991; 21 77-80.

  54. SMITH WL, DEWITT DL, SHIMOKAWA T. MOLECULAR-BASIS FOR THE INHIBITION OF PROSTANOID BIOSYNTHESIS BY NONSTEROIDAL ANTIINFLAMMATORY AGENTS STROKE. 1990.12; 21 (12): 24-28.

  55. SHIMOKAWA T, KULMACZ RJ, DEWITT DL, SMITH WL. TYROSINE-385 OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE IS REQUIRED FOR CYCLOOXYGENASE CATALYSIS JOURNAL OF BIOLOGICAL CHEMISTRY. 1990.11; 265 (33): 20073-20076.

  56. SMITH WL, DEWITT DL, KRAEMER SA, ANDREWS MJ, HLA T, MACIAG T, SHIMOKAWA T. STRUCTURE-FUNCTION-RELATIONSHIPS IN SHEEP, MOUSE, AND HUMAN PROSTAGLANDIN ENDOPEROXIDE G/H SYNTHASES ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH. 1990; 20 14-21.

  57. SHIMOKAWA T, MORIUCHI A, HORI T, SAITO M, NAITO Y, KABASAWA H, NAGAE Y, MATSUBARA M, OKUYAMA H. EFFECT OF DIETARY ALPHA-LINOLENATE LINOLEATE BALANCE ON MEAN SURVIVAL-TIME, INCIDENCE OF STROKE AND BLOOD-PRESSURE OF SPONTANEOUSLY HYPERTENSIVE RATS LIFE SCIENCES. 1988; 43 (25): 2067-2075.

  58. NAKAGAWA M, ISHIHARA N, SHIMOKAWA T, KOJIMA S. EFFECT OF CLOFIBRATE ON LIPID-PEROXIDATION IN RATS TREATED WITH ASPIRIN AND 4-PENTENOIC ACID JOURNAL OF BIOCHEMISTRY. 1987.01; 101 (1): 81-88.

▼全件表示

このページの先頭へ▲

書籍等出版物 【 表示 ／ 非表示 】

  1. Teruhiko Shimokawa, William L. Smith. Amino Acids Essential to Catalysis by Prostaglandin Endoperoxide Synthase. Springer Science+Business Media New York, 1991 (ISBN : 978-1-4899-0727-1)

  2. 下川 晃彦　他. 平成29年度 (2017年度) 創薬技術調査　国外調査報告書「デジタルヘルス時代における創薬の新たな潮流を探る」　ー欧米での創薬エコシステム、データサイエンスおよび創薬基盤改革の進展を中心にー. 公益財団法人ヒューマンサイエンス振興財団, 2018.03

  3. 下川晃彦 他. 平成28年度 (2016年度) 国外調査報告書「革新的疾患治療法・診断法開発の新たな潮流を探る」ー個別化医療、新規モダリティ医薬品開発 及び 産学官連携の動向ー. 公益財団法人ヒューマンサイエンス振興財団, 2017.03

  4. 鞍馬岳吏, 下川晃彦. 摂食調節ペプチド【マロニィル-CoAと摂食制御機構】. ニューサイエンス社; 細胞, 2005.10

  5. 下川晃彦. 脂質代謝の分子制御 PPARβ. Medical Review Co., Ltd.; The Lipid, 2000.02

  6. 編集者; 板倉弘重, 執筆者; 新井洋由，井上圭三, 今泉勝己, 下川晃彦, 菅野道廣, 寺本民生, 西島正弘, 松澤佑次, 山本章, 他. 脂質の科学. 朝倉書店, 1999.03 Cholesterol Metabolism (ISBN : 978-4-254-43514-6)

  7. 船津敏之, 田中秀之, 臼田真治, 後藤正英, 西嶋智見, 井田素子, 下川晃彦. HepG2細胞における新規HMG-CoA還元酵素阻害薬YM548のLDL受容体活性およびLDL受容体遺伝子発現量に対する作用. SUNMEDIA; 薬理と治療, 1998.09

  8. 下川晃彦, 児玉龍彦, 板倉広重. 循環器疾患と遺伝子解析 コレステロール代謝異常と遺伝子異常. 現代医療, 1995.05

▼全件表示

このページの先頭へ▲

講演・口頭発表等 【 表示 ／ 非表示 】

  1. T. Shimokawa, M.V.Kumar, M.D.Lane, The Johns Hopkins University School of Medicine, Department of Biological Chemistry, Baltimore, USA. Effect of the fatty acid synthase inhibitor, C75, on neuropeptide mRNA levels in hypothalamus of ob/ob mice.. Keystone Symposia 2002 at Colorado USA 2002.01.14

  2. M.V.Kumar, T. Shimokawa, M.D.Lane, The Johns Hopkins, University School of, Medicine Department of Biological Chemistry, Baltimore, USA. Chronic effects of C75, a fatty acid synthase inhibitor, in obese but not in lean mice.. Keystone Symposia 2002 at Colorado USA 2002.01.13

  3. T. Shimokawa, M.V.Kumar, M.D.Lane, The Johns Hopkins University School of Medicine, Department of Biological Chemistry, Baltimore, USA. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides.. Keystone Symposia 2002 at Colorado USA 2002.01.12

  4. T. Shimokawa, M.V. Kumar, and M.D. Lane. Effect of a fatty acid synthase inhibitor, C75, on neuropeptide mRNA levels in hypothalamus of ob/ob mice.. Keystone Symposia 2002 at Colorado USA 2002.01.12

  5. M. Kato, Y. Watanabe, Y. Ueda, M. Ida, M. Goto, S. Nishijima, T. Shimokawa, S. Hashimoto, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co., Ltd, Tsukuba Ibaraki Japan. Effect of thyroid hormone on muscle-specific gene regulation at mRNA level during myoblast differentiation.. The Endocrine Society, 80th Annual Meeting at New Orleans, LA, USA 1998.06.25 New Orleans, USA

  6. T. Shimokawa, M. Kato, Y. Iijima, J. Irie, K. Shioduka, Y. Ueda, M. Ida, H.-T. Ma, S. Hashimoto, O. Ezaki, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co., Ltd, Tsukuba Ibaraki Japan, The Clinical Nutrition, The National, Institute for Health, Nutrition, Tokyo, Japan. Triiodothyronine treatment increases glucose transporter isotype 4 and MyoD mRNA levels in skeletal muscle of KK mice.. The 57th Annual Meeting of American Diabetes Association in Boston, MA (USA) 1997.07.22 Boston, USA

  7. T. Shimokawa, S. Goto, T. Ugawa, N. Hisamichi, Y. Iizumi, O. Inagaki, N. Sato, T. Takenaka, T. Kodama, Molecular Medicine Laboratories, Yamanouchi Pharmaceutical Co. Ltd, Tsukuba Ibaraki Japan, The Third Department of Internal Medicine, The University of Tokyo, Tokyo Japan. Potent hypocholesterolemic effect of YM-16638 in monkeys.. XII International Symposium on Drugs Affecting Lipid Metabolism, at Houston Texas, USA. Top 20 in the Young Investigator Award. 1995.11.08

  8. Y. Kawabe, T. Shimokawa, T. Kodama. Sterol mediated regulation of SREBP-1a, 1b, 1c and SREBP-2 in cultured human cells.. FASEB Seminar 1995

  9. W. L. Smith, T. Shimokawa, Department of Biochemistry, Michigan State University, East Lansing, MI USA. The Prostaglandin G/H Synthase. XIth Washington International Spring Symposium; "Prostaglandins, Leukotrienes, Lipoxins & PAF '91" 1991.03.15

  10. T. Shimokawa, W. L. Smith, Department of Biochemistry, Michigan State University, East Lansing, MI USA. Site-directed mutagenesis in active site serine of prostaglandin G/H synthase. The 20th Annual Michigan Cardiovascular Research Forum (AHA) 1990.09.11

  11. 下川晃彦. 実用化に向けたアカデミアパートナリング活動 ～ 海外実践編 ～. AMED 医療分野の成果導出に向けた研修セミナー オープン講座 ー海外商談会に向けた実務者向け講座ー 2022.03.23 東京

  12. T. Shimokawa, T. Kurama, I. Aramori, M. Daniel Lane. The regulation of food intake by Malonyl-CoA in hypothalamus.. The Joint Conference of The 32th Annual Meeting of The Neuroendocrine Society of Japan and The 20th Annual Meeting of The Pituitary Gland Society of Japan at Okinawa 2005.06.07

  13. M.Goto, M.Kato, T. Shimokawa. Gene expression analysis of a transcriptional coactivator PGC-1 in skeletal muscle of an exercised rat.. The 23th Annual Meeting of The Molecular Biology Society of Japan at Kobe 2000.12.15

  14. 香川 靖雄, 車 昇勲, 加藤 美雪, 下川 晃彦, 長谷川 恭子. 糖尿病の分子機構　糖尿病マウスのn-3多価不飽和脂肪酸による脱共役蛋白質の増加. 生化学 1999.08.01

  15. S. Goto, T. Shimokawa. The mechanism of cholesterol-lowering effect of YM-16638.. The 28th Annual Meeting of the Japan Atherosclerosis Society 1996

  16. 下川 晃彦. ステロールによるHMG-CoA合成酵素,Mevalonateキナーゼ,Farnesylpyrophosphate合成酵素の転写制御. 動脈硬化 1994.10.01

  17. 下川 晃彦. コレステロール負荷ラットの肝及び血漿脂質に対するマコモ(Zizania latifolia)の影響. 日本薬学会年会要旨集 1987.03.01

▼全件表示

このページの先頭へ▲
 

教育上の能力に関する事項 【 表示 ／ 非表示 】

  • 実用化に向けたアカデミアパートナリング活動 ～ 海外実践編 ～ ，2022年03月

このページの先頭へ▲

職務上の実績に関する事項 【 表示 ／ 非表示 】

  • 日本神経学会主催 産官学創薬スクール「神経疾患に対する創薬トランスレーショナルリサーチを学ぶ」，2024年02月

  • 難治性自己免疫疾患に関する共同研究締結 <Human Life Cord 株式会社> ～難治性自己免疫疾患に新たな治療選択肢を～，2023年03月 - 2024年06月

  • 先端バイオイメージングAI研究会，2022年08月 - 2023年09月

  • AMED革新的医療技術研究開発推進事業ワークショップ（研究開発統括推進室 基金事業課）産学連携コーディネーター担当（支援），2022年05月

  • AMED医療分野の成果導出に向けた研修セミナー オープン講座; 海外商談会に向けた実務者向け講座 講演（講師），2022年03月

このページの先頭へ▲